These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 9729692)

  • 1. Adolescents on neuroleptic medication: is this population at risk for tardive dyskinesia?
    McDermid SA; Hood J; Bockus S; D'Alessandro E
    Can J Psychiatry; 1998 Aug; 43(6):629-31. PubMed ID: 9729692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study.
    Morgenstern H; Glazer WM
    Arch Gen Psychiatry; 1993 Sep; 50(9):723-33. PubMed ID: 8102845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The current prevalence and factors associated with tardive dyskinesia among Filipino schizophrenic patients.
    Go CL; Rosales RL; Caraos RJ; Fernandez HH
    Parkinsonism Relat Disord; 2009 Nov; 15(9):655-9. PubMed ID: 19346155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of and risk factors for tardive dyskinesia in a Xhosa population in the Eastern Cape of South Africa.
    Patterson BD; Swingler D; Willows S
    Schizophr Res; 2005 Jul; 76(1):89-97. PubMed ID: 15927802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective study of tardive dyskinesia in the elderly: rates and risk factors.
    Woerner MG; Alvir JM; Saltz BL; Lieberman JA; Kane JM
    Am J Psychiatry; 1998 Nov; 155(11):1521-8. PubMed ID: 9812112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of tardive dyskinesia and tardive dystonia in African Caribbean patients on long-term antipsychotic treatment: the Curaçao extrapyramidal syndromes study V.
    van Harten PN; Hoek HW; Matroos GE; van Os J
    J Clin Psychiatry; 2006 Dec; 67(12):1920-7. PubMed ID: 17194270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients.
    Richardson MA; Haugland G; Craig TJ
    Am J Psychiatry; 1991 Oct; 148(10):1322-8. PubMed ID: 1680296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
    Gharabawi GM; Bossie CA; Zhu Y; Mao L; Lasser RA
    Schizophr Res; 2005 Sep; 77(2-3):129-39. PubMed ID: 15913962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substance abuse as a risk factor for tardive dyskinesia: a retrospective analysis of 1,027 patients.
    Bailey LG; Maxwell S; Brandabur MM
    Psychopharmacol Bull; 1997; 33(1):177-81. PubMed ID: 9133772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroleptic withdrawal in treatment-resistant patients with schizophrenia: tardive dyskinesia is not associated with supersensitive psychosis.
    Apud JA; Egan MF; Wyatt RJ
    Schizophr Res; 2003 Sep; 63(1-2):151-60. PubMed ID: 12892869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent tardive dyskinesia: demographic and pharmacological risk factors.
    Muscettola G; Pampallona S; Barbato G; Casiello M; Bollini P
    Acta Psychiatr Scand; 1993 Jan; 87(1):29-36. PubMed ID: 8093821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curaçao Extrapyramidal Syndromes Study III.
    van Harten PN; Hoek HW; Matroos GE; Koeter M; Kahn RS
    Am J Psychiatry; 1998 Apr; 155(4):565-7. PubMed ID: 9546009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study.
    Sachdev P
    Aust N Z J Psychiatry; 2004 Jun; 38(6):445-9. PubMed ID: 15209837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tardive dyskinesia: who is at risk?
    van Os J; Fahy T; Jones P; Harvey I; Toone B; Murray R
    Acta Psychiatr Scand; 1997 Sep; 96(3):206-16. PubMed ID: 9296552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A survey of tardive dyskinesia in psychiatric inpatients in Japan.
    Koshino Y; Madokoro S; Ito T; Horie T; Mukai M; Isaki K
    Clin Neuropharmacol; 1992 Feb; 15(1):34-43. PubMed ID: 1349507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case series: spectrum of neuroleptic-induced movement disorders and extrapyramidal side effects in childhood-onset schizophrenia.
    Kumra S; Jacobsen LK; Lenane M; Smith A; Lee P; Malanga CJ; Karp BI; Hamburger S; Rapoport JL
    J Am Acad Child Adolesc Psychiatry; 1998 Feb; 37(2):221-7. PubMed ID: 9473920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Not all that moves is tardive dyskinesia.
    Khot V; Wyatt RJ
    Am J Psychiatry; 1991 May; 148(5):661-6. PubMed ID: 1673323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.
    Tollefson GD; Beasley CM; Tamura RN; Tran PV; Potvin JH
    Am J Psychiatry; 1997 Sep; 154(9):1248-54. PubMed ID: 9286184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications.
    Glazer WM; Morgenstern H; Doucette JT
    J Clin Psychiatry; 1993 Apr; 54(4):133-9. PubMed ID: 8098030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients.
    Jeste DV; Lacro JP; Bailey A; Rockwell E; Harris MJ; Caligiuri MP
    J Am Geriatr Soc; 1999 Jun; 47(6):716-9. PubMed ID: 10366172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.